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Abstract
The hepatitis C virus (HCV) is a causal agent of chronic liver infection, cirrhosis, and hepatocellular carcinoma infecting more than 170
million people. CD81 is a receptor for HCV envelope glycoprotein E2. Although the binding of HCV-E2 with CD81 is well documented
the role of this interaction in the viral life cycle remains unclear. Host specificity and mutagenesis studies suggest that the helix D region
of CD81 mediates binding to HCV-E2. Structural analysis of CD81 has enabled the synthesis of small molecules designed to mimic the
space and hydrophobic features of the solvent-exposed face on helix D. Utilizing a novel bis-imidazole scaffold a series of over 100
compounds has been synthesized. Seven related, imidazole-based compounds were identified that inhibit binding of HCV-E2 to CD81. The
inhibitory compounds have no short-term effect on cellular expression of CD81 or other tetraspanins, do not disrupt CD81 associations with
other cell surface proteins, and bind reversibly to HCV-E2. These results provide an important proof of concept that CD81-based mimics
can disrupt binding of HCV-E2 to CD81.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Hepatitis C virus (HCV) is a positive-strand RNA virus
that infects approximately 170 million people worldwide.
The majority of those infected fail to clear the virus and in
many cases the chronic infection with HCV leads to cirrho-
sis or liver cancer (Freeman et al., 2001; Memon and
Memon, 2002; Rosenberg, 2001). There is no vaccine for
HCV and current therapeutic strategies yield roughly 40%
response rates. HCV prevalence in the United States is
expected to triple by 2010. The mechanisms of HCV infec-
tion and evasion of a successful immune response are not
well understood.
Recently the cell surface protein CD81 was identified as
a binding partner for the HCV envelope protein E2 (Flint et
al., 1999a, 1999b, 2000; Pileri et al., 1998). CD81 is a
member of the tetraspanin family of integral membrane
proteins (Levy et al., 1998; Maecker et al., 1997; Wright
and Tomlinson, 1994). The binding of HCV-E2 to CD81
has been demonstrated with recombinant HCV-E2, HCV
E1-E2 complexes, HCV pseudoparticles, as well as “bona
fide” viral particles (Bartosch et al., 2003; Chan-Fook et al.,
2000; Dhanasekaran et al., 2003; Drummer et al., 2002;
Flint et al., 1999a; Forns et al., 2000; Higginbottom et al.,
2000; Meyer et al., 2000; Owsianka et al., 2001; Patel et al.,
2000; Petracca et al., 2000; Pileri et al., 1998; Triyatni et al.,
2002). These sources of HCV-E2 bind to either recombinant
soluble forms of the large extracellular loop (LEL) of CD81
or to native CD81 expressed on the surface of cells and
HCV-E2 binding to cells can be blocked by antibody to
CD81 or by preincubation with CD81-LEL (Bartosch et al.,
2003; Flint et al., 1999a; Owsianka et al., 2001; Pileri et al.,
1998; Triyatni et al., 2002). Interestingly, the infection of
primary human hepatocytes is inhibited by anti-CD81 mAb
or by CD81-LEL (Bartosch et al., 2003). Immunization of
chimpanzees with HCV-E2 elicits protective antibodies
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which bind to HCV-E2 in such a way as to block interaction
with CD81, whereas animals whose anti-HCV-E2 antibod-
ies failed to block binding to CD81 were not protected from
infection (Pileri et al., 1998). Recent work has shown that
specific strains of HCV (1a in particular) bind more effec-
tively to CD81 and that the interaction is mediated by the
hypervariable 1 and 2 regions of HCV-E2 (Roccasecca et
al., 2003). Data from hCD81 transgenic mice and in tama-
rins indicate that CD81 binding to HCV-E2 alone is not
sufficient for infection (Allander et al., 2000; Masciopinto et
al., 2002; Meola et al., 2000).
The role of HCV-E2 binding to CD81 during HCV
infection is not known. One possibility is that HCV-E2
binding to CD81 may facilitate virus internalization and/or
membrane fusion. Another possibility is that HCV-E2 bind-
ing to CD81 may exert regulatory effects on the immune
response where CD81 is known to possess functionally
important roles (Levy et al., 1998). Antibody cross-linking
of CD81 on B cells or T cells provides costimulation with
the antigen receptor and promotes activation and prolifera-
tion of these cells (Lagaudriere-Gesbert et al., 1997; Wack
et al., 2001; Witherden et al., 2000). Similarly the binding of
HCV-E2 to T cells has been shown to provide costimulation
(Wack et al., 2001). It is noteworthy that binding of
HCV-E2 to CD81 on NK cells suppresses their activation
(Crotta et al., 2002; Tseng and Klimpel, 2002). The immu-
nomodulatory effects of HCV-E2 may enable the virus to
evade an immune response and may contribute to extrahe-
patic lymphoproliferative disorders that are associated with
HCV infection (Freeman et al., 2001).
Understanding the structural requirements for the inter-
action of HCV-E2 and CD81 was rapidly advanced by the
finding that CD81 of African green monkey (AGM) does
not bind HCV-E2, whereas both chimpanzee and human
CD81 do bind HCV-E2 (Flint et al., 1999a; Higginbottom et
al., 2000; Patel et al., 2000). The human and AGM CD81
sequences differ at only four residues and mutagenesis ex-
periments have confirmed the contribution of these amino
acids to the interaction with HCV-E2 (Higginbottom et al.,
2000). All four sequence differences are found in the second
extracellular loop of CD81. The crystal structure of the
second extracellular loop of CD81 reveals that the key
amino acids involved in HCV-E2 binding are predicted to
project from the solvent-exposed face of a short helical
region called helix D (Kitadokoro et al., 2001a, 2001b).
Subsequent work confirmed the helix D region (residues
I182, N184, and F186 in particular) as important for binding to
HCV-E2 (Drummer et al., 2002).
We considered the possibility that molecules designed to
mimic CD81 helix D may be able to competitively bind to
HCV-E2 and, by occupying the CD81 binding domain,
compete for the binding of HCV-E2 to native CD81 ex-
pressed on cells. We have recently reported structural char-
acterization of CD81 helix D peptides and demonstrated the
ability of CD81 peptides to block HCV-E2 binding to cells
(Dhanasekaran et al., 2003). Herein we report the synthesis
of compounds structurally related by a common imidazole-
4,5-dicarboxamide (I45DC) scaffold and presenting CD81
helix D amino acid side chains which act as competitive
inhibitors of HCV-E2 binding to human CD81.
Results
Recombinant HCV-E2 binds to CD81 on Molt-4 T cells
We employed a sensitive assay that quantifies the ability
of different CD81 mimics to block HCV-E2 binding to
cellular CD81. The binding of recombinant HCV-E2 to the
human T-cell line Molt-4 was measured by detection with
biotinylated anti-E2 mAb 6F6 followed by strepavidin con-
jugated to Alexa 488 (Fig. 1A) or by nonconjugated mAb
6F6 followed by goat antimouse conjugated to Alexa 488
(Fig. 1B). Flow cytometry was then used to measure the
Fig. 1. Recombinant HCV-E2 binds to CD81 at physiologic temperatures. T cells were preincubated with antibodies against CD81 5A6 (dotted line), JS81
(dashed line), or control mAbs (solid line) prior to incubation with 5 g/ml HCV-E2 and detection by anti-E2 6F6-biotin followed by streptavidin-PE and
flow cytometric analysis. Shaded histogram represents no E2 negative control. The dotted and dashed lines are directly overlapping the negative control (A).
T cells were incubated with increasing doses of E2 at 37°C (closed squares) or at 4°C (open triangles) and detected with 6F6 followed by goat antimouse
Alexa 488 and analyzed by flow cytometry (B).
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extent of cell-bound HCV-E2. Consistent with published
reports, we find that HCV-E2 binds specifically to CD81 on
cells (Flint et al., 1999a; Higginbottom et al., 2000; Pileri et
al., 1998; Roccasecca et al., 2003). To validate the speci-
ficity of the assay we blocked CD81 with mAbs 5A6 or
JS.81 or with isotype control mAb prior to adding HCV-E2
and detecting with biotinylated 6F6 (Fig. 1A). The biotin-
ylated 6F6 was used to avoid cross-reactivity of the block-
ing mAb (5A6 or JS.81) with the detecting goat antimouse
Alexa 488. Similar results were obtained when using anti-E2
mAb H53 to detect binding (data not shown). Incubating the
cells with higher (but submaximal) doses of HCV-E2 results
in an increase of detectable cell-bound E2 over a range of 0
to 5 g/ml (Fig 1B). The fact that the binding of HCV-E2
to CD81 is greatly improved at 37°C is consistent with the
interaction being driven by hydrophobic forces that are
more influential at higher temperatures and as such equilib-
rium binding is achieved in a shorter time (Roccasecca et
al., 2003). The use of Alexa-488 and optimal binding tem-
perature resulted in a roughly 50-fold improvement in the
sensitivity of the binding assay allowing us to detect subtle
differences in the amount of HCV-E2 bound to cells and
allowing a more precise determination of the effectiveness
of different CD81 mimics to block HCV-E2 binding to
cellular CD81.
Development of I45DC mimics of helix D
We previously reported the structural characterization of
CD81 helix D peptides and have demonstrated their ability
to inhibit the binding of HCV-E2 to CD81 (Dhanasekaran et
al., 2003). Our efforts then turned to identifying a scaffold
capable of presenting either amino acids or other structures
in a similar orientation and spatial arrangement as the sol-
vent exposed hydrophobic ridge of helix D. The objective
was to identify a scaffold and amino acid side chains with
the potential to disrupt the binding of HCV-E2 to CD81.
Imidazole is a common structural component of many bio-
logically active compounds. Substituted imidazoles have
diverse bioactivities making them useful small molecules
for lead structure identification in drug discovery (Bog-
danova et al., 1991; Borodkin Yu et al., 1984; Reikhardt and
Kulikova, 1994; Yasuda et al., 1983). We have previously
reported the use of symmetric N, N’ -disubstituted imida-
zole-4,5-dicarboxamides (I45DCs) in a study on heterocy-
clic HIV-1 protease inhibitors (Baures, 1999). The I45DC
scaffolds are relatively simple to prepare, have predictable
conformations, and are amphiphilic (Wiznycia and Baures,
2002). The 145DCs form a reliable intramolecular hydrogen
bond in solution that results in a conformation that presents
amide group substituents in comparable fashion to side-
chain separations in an idealized -helix (Fig. 2B and C).
This was confirmed by X-ray crystallographic data showing
a similar distance between the two substituents on the imi-
dazoles as compared with the C -C distance (6.3 Å)
between adjacent side chains on the same face of an ideal 
-helix. Several structural classes were synthesized in an
effort to discover the best 145DC scaffolds to use as optimal
mimics of CD81. The separation between the amide groups
of compounds 1–4 (Fig. 3A) approximates 3.8 Å, which is
the distance between two amino acid side chains in tandem
on an -helix (Fig. 2B). Compounds 5–34 (Fig. 3B, C)
employ two imidazole rings connected by a linker. The
imidazole rings can stack upon each other via hydrogen
bonds and the distance and flexibility between the stacked
rings is controllable by the choice of linker. Each ring in
compounds 5–34 can present two amino acid groups as in
compounds 1–4 for a total of four amino acid groups per
compound. Flexibility in the linking group allows the com-
pound to probe for a “best fit” with the target protein,
HCV-E2. At the same time this flexibility implies that only
a fraction of these molecules will be in the inhibitory con-
Fig. 2. Structure of CD81-EC2 and I45DC-based CD81 mimic. Backbone structure of the second extracellular loop of CD81 with selected side chains in helix
D shown in the putative region of HCV-E2 binding (A). Distances between select hydrophobic side chains in CD81 helix D as determined from an ideal
-helix backbone (B). A mimic of the -helix created by the connection of two imidazole rings through a linker and presenting amino acid side chains from
the imidazole ring substituents. Note that the diagram shows one conformation although alternative conformations can occur by either rotating one imidazole
ring with respect to the other or through the formation of different hydrogen bonds or both (C).
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formation and thus the concentration of the active species
will be lower than the total concentration. It is noteworthy
that the conformational behavior of these compounds is
evident by comparing the 1H NMR spectrum of each. The
proton resonances of compounds with shorter less flexible
linking groups (Fig. 3, compounds 5–16) are relatively well
resolved in comparison, making them more conformation-
ally invariant on the NMR time scale (not shown). Addition
of linkers having secondary amines and leading to tertiary
amides results in additional conformational restriction as
well as having the possibility of presenting a potential side
chain mimic off of the linker nitrogens. Compounds 27–34
explore the use of an alternate linker. The hydrophobic side
chains of helix D were expected to be part of the binding
interface and Ile, Leu, Phe, and Val were included in our
substituent list (Fig. 3D). We considered it possible that the
native amino acid groups of CD81 helix D might sterically
interfere with proper stacking of the imidazole rings and
because it is also possible that a residue could be substituted
without compromising its binding to HCV-E2 we included
Ala, Gly, and Val as a smaller substituents that might avoid
steric hindrance but retain binding activity.
I45DC compounds block binding of HCV-E2
to CD81 on cells
Compounds 1–4 were expected to mimic two side chains
of helix D. However, none of these compounds showed any
bioactivity in the binding assay (Fig. 4A). In contrast, 13
demonstrates activity in the micromolar concentration range
(Fig. 4A and B). The linker length was found to be impor-
tant as extension by even a single methylene unit to yield 21
results in loss of activity (Fig. 4A). Compound 7 has sig-
nificantly improved bioactivity over 13 resulting in almost
complete blocking of HCV-E2 binding to CD81 (Fig. 4A
and B). Compounds 7 and 13 are identical except for an
ethyl group at the R position in 7, which may contribute to
better stability in the linker at the active conformation. The
activity of 7 is dose dependent with an EC50 of 53 M (Fig.
5A). To explore the possible role of the benzyl ester sub-
stituent as a phenylalanine side chain mimic, 6 and 8 were
prepared. Compound 6 with a tert-butyl ester blocks bind-
ing, albeit to a lesser extent, whereas 8 with a methyl ester
has equivalent bioactivity to 7 (Fig. 4A and B). We were
able to improve the bioactivity of 7 by making a modifica-
Fig. 3. Structure of I45DC based mimics of helix D. Compounds 1–4 (A) were synthesized with two side chains (R) separated by 3.8 Å (the distance between
adjacent amino acid side chains in an -helix). Connecting two I45DC scaffolds with a linker of varying length (n) yields compounds 5–26 (B). The link
provides some flexibility such that the two side chains (R) can assume a desirable spatial conformation for HCV-E2 interaction. Compounds 27–34 provide
an alternate linker design (C). A table of the linker length (n) and side chain mimics (R and R) used in A–C (D). The side chains (R) contain an amino acid
linked to a tert-butyl (O Bu), ethyl (OEt), methyl (OMe), or benzyl ester (OBzl).
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tion to the side chain, finding that the Leu analog, 5, has
improved bioactivity (Fig. 4A and B) with an EC50 of 38
M (Fig. 5B). The ethyl group in the linker for 7 contributes
to the inhibition as evidenced by the lower activity of 13.
We hypothesize that the ethyl linker may be important for
the proper conformation between imidazole rings in order to
present the amino acid side chains or for its own interactions
with the HCV-E2 protein.
Alternative interpretations of the blocking effect of
compounds 7 or 5 on HCV-E2–CD81 binding
Exhaustive effort was given to alternative interpretations
of the blocking data. Could it be nonspecific in some way?
Not likely. Because we have tested very similar compounds
under exactly the same conditions but without inhibition
they serve as outstanding negative controls. Blocking com-
pounds, including 7 and 5, were even synthesized a second
time and retested to assure that nothing in the synthesis was
unique. Although the compounds exceed 90% purity we
even purified the trace impurities and tested them but the
trace impurities do not show blocking activity. We won-
dered if the fact that the compound was exposed to cells
during the binding assay could allow the compound to
interact with the cells, perhaps directly with CD81, and
inhibit the binding of HCV-E2 by some indirect mecha-
nism. This too is unlikely. We pretreated cells with com-
pound 7 for various periods of time (even exceeding the
incubation periods used in the binding assay) and washed
before adding HCV-E2 but the pretreated cells still bound
HCV-E2 at levels equal to nontreated cells (Fig. 6A). In all
experiments DMSO was included in the negative controls at
equal concentrations to the experimental samples. To ensure
that cell viability was not an issue, within the relatively
short time frame of the binding assay, Molt-4 cells were
incubated with the compounds and analyzed for trypan blue
exclusion. No loss in cell viability was detected (data not
shown). CD81 binds to other tetraspanins and multiple
surface proteins forming complexes known as the tet-
raspanin web (Boucheix and Rubinstein, 2001; Charrin et
al., 2002; Rubinstein et al., 1996). We tested the effects of
compounds on tetraspanin expression (CD9, CD53, CD63,
CD81, CD82, and CD151) and reactivity of these cell sur-
face proteins with mAbs. Treatment of cells with I45DCs
does not interfere with the ability of anti-CD81 mAbs or
other antitetraspanin mAbs to bind their target epitopes on
these proteins (Fig. 6B). Therefore the inhibitory effect of 7
and 5 is not due to modulation of CD81 or known tet-
raspanin partners that may be complexed with CD81. Nor is
the effect attributable to conformational changes in CD81 as
measured by reactivity with anti-CD81 mAbs. We have also
evaluated the effect of 7 on CD81 associations with other
Fig. 4. Activities of I45DC-based mimics of CD81 helix D. HCV-E2 (5 g/ml) was incubated with the indicated compound and then added to 5 105 Molt-4
cells. Compounds were present on cells at 500 M and 6% DMSO for 30 min at 37°C. Cells were then washed, iced, and 1 g H53 or 6F6 was added in
0.1 ml PBS followed by another wash before detecting with goat antimouse Alexa 488 and flow cytometry. Percentage activity for each drug was calculated
from MFI values as the percentage decrease in HCV-E2 binding with 100% as E2 binding in the absence of I45DC compound and 0% as the cells only
negative control (A). Gray histograms represent negative control with no E2, solid-line histograms are the positive controls that include 6% DMSO, and the
dotted-line histograms represent the blocking effect of the compound. Data are representative of a minimum of three experiments (B).
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proteins on the cell such as PGRL (Clark et al., 2001). Using
our published biotin labeling and CD81 coimmunoprecipi-
tation protocol we find that treatment of the cells with 7 has
no effect on the amount of CD81 recovered in the immu-
noprecipitation and no effect on the association of CD81
with PGRL (Fig. 6C). Taken together these data indicate
that 7 is not altering the expression of CD81 or disrupting
CD81 complexes during the timeframe in which 7 shows
inhibitory effects on HCV-E2 binding to CD81.
To address the other side of the interaction we consid-
ered possible effects of compounds on HCV-E2. As noted
above, the possibility that 5 or 7 nonspecifically interferes
with HCV-E2 activity is highly unlikely because other,
nearly identical compounds, such as 9, 12, or 16, do not
exhibit inhibitory activity. Further evidence that active com-
pounds do not nonspecifically modify or permanently alter
HCV-E2 activity is shown by the finding that the blockade
of HCV-E2 by 5 is reversible. HCV-E2 was treated with 5
under exactly the same conditions which inhibit binding to
cells and was then captured by H53-coated plastic, rinsed,
and then tested for HCV-E2 mediated costimulation of
human T cells. Pretreated and washed HCV-E2 provided
costimulation equaling that of nontreated HCV-E2, which
shows that the inhibitor is reversible and shows that binding
to the inhibitor does not impair the ability of H53 to bind
HCV-E2 (Fig. 6D).
The obvious next stage of testing for these compounds is
to determine whether they inhibit HCV-E2-induced cellular
functions or HCV infectivity. The current series of com-
pounds requires 6% DMSO to remain in solution and this
feature complicates longer term (12 h) cell culture assays
or in vivo studies. Challenges in solubility are not surprising
considering the hydrophobic nature of the face of CD81
helix D which these compounds are designed to mimic.
Continued structure–function analysis is underway to iden-
tify substitutions or linker modifications which may im-
prove the solubility of these compounds while retaining or
improving their inhibitory activity. Despite this challenge
the present data offer an important proof of concept that
small molecules designed to mimic the solvent exposed face
of helix D can inhibit the binding of HCV-E2 to cell surface
expressed CD81.
Discussion
The mechanism of HCV entry into cells is not known.
The binding of HCV-E2 to CD81 is unlikely to determine
the tropism of the virus but may trigger internalization or
enable membrane fusion, perhaps in cooperation with an-
other binding partner. Interestingly, CD81 may contribute to
membrane fusion events during myoblast differentiation
and CD9, a tetraspanin closely related to CD81, plays an
important role in sperm–egg fusion during fertilization
(Kaji et al., 2000; Le Naour et al., 2000; Miyado et al.,
2000; Tachibana and Hemler, 1999).
The binding of HCV-E2 to CD81 expressed on T cells
and NK cells alters the activation state of these cells and
may contribute to the ability of HCV to evade host immune
response (Crotta et al., 2002; Flint et al., 1999a; Tseng and
Klimpel, 2002; Wack et al., 2001). Interestingly, HCV-E2
binding to CD81 on T cells provides costimulation, whereas
the same interaction suppresses NK cell activity. NK cells
represent a first line of defense against viral infection and
thus their suppression by HCV-E2 may be a viral tactic
allowing HCV to gain an early foothold in the host.
Here we report the synthesis of bis-imidazole-based
compounds intended to mimic the solvent-exposed face of
CD81 helix D. These I45DC scaffolds represent both a
novel scaffold as well as an unexplored approach in scaffold
design—namely the use of noncovalent forces in water to
predictably control the presentation of the pharmacophoric
Fig. 5. Titration of 7 and 5 inhibitory activity. HCV-E2 (5 g/ml) was
mixed with indicated compound, incubated at 37°C, and then added to 5 
105 Molt-4 cells. Compounds were present on cells at the indicated con-
centrations with 6% DMSO for 30 min at 37°C. Cells were then washed,
iced, and 1 g H53 or 6F6 was added in 0.1 ml PBS and detected with goat
antimouse Alexa 488. Gray histogram represents negative control with no
E2, the bold-line histogram (rightmost) is the positive control that includes
6% DMSO, and the solid-line histograms (decreasing in order with the
dilutions) represent the dilutions of the indicated compound. EC50s were
calculated as the concentration of compound required to block 50% of
specific binding using one phase exponential decay nonlinear regression.
Values are representative of three different experiments.
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functional groups appended to the scaffold backbone. Flex-
ibility in the linking group allows I45DCs to probe for a
“best fit” with the target protein, HCV-E2. At the same time
this flexibility implies that only a fraction of these mole-
cules will be in the inhibitory conformation and thus the
concentration of the active species will be lower than the
total concentration. Therefore it is possible that the inhibi-
tory effect of 7 or 5 may be greatly improved by substitution
of a less flexible linking group capable of presenting the
“best” ring orientation.
Several compounds in this series were found to have
activity in disrupting the binding of HCV-E2 to CD81. Our
initial structure–activity analysis provides some indication
of the features required for CD81 mimicry. Accurate pre-
sentation of two side chains alone does not appear to be
sufficient (evidenced by the inactivity of 1–4). The signif-
icance of both accurate side-chain presentation combined
with specific linker features is supported by the activity of
13 and loss of activity in 21, 23, and 26. We note that 13 can
adopt a variety of conformations due to its flexible linker
and freedom to stack the imidazole rings according to dif-
ferent hydrogen bond patterns. Fewer conformational iso-
mers are expected in 7 due to the controlled direction of the
intramolecular hydrogen bond and the additional steric con-
straints on the ethylamine linker resulting from the tertiary
amides.
This is the first report of a small molecule designed to
mimic CD81 in order to disrupt the interaction of HCV-E2
and CD81. This strategy of utilizing compounds that block
receptor interaction has proven useful in other viral systems,
including HIV, where compounds designed to bind an in-
termediate conformation of gp41 and coreceptor antagonists
are finding success in clinical trials (De Clercq, 2001). The
discovery of inhibitory activity and selectivity among the
bis-imidazole-based compounds reported here suggests that
the approach is feasible and offers hope that further explo-
Fig. 6. The blocking effect of 7 or 5 on HCV-E2–CD81 binding results from a specific and reversible interaction. Molt-4 T cells were incubated with 455
M compound 7 (dotted-line histogram) or 6% DMSO only (gray and solid-line histograms) for 30 min at 37°C, washed with PBS, and incubated with 5
g/ml E2 (gray histogram without E2) and detected with H53 and goat antimouse Alexa 488 (A). Molt-4 T cells were incubated with 50 M compound 7
(dotted-line histogram), compound 5 (dashed-line histogram) or 1% DMSO only (shaded histogram) for 24 h. Tetraspanin expression levels were detected
with anti-tetraspanin mAbs and goat antimouse Alexa 488 (B). Jurkat T cells were incubated with (lane 2) or without (lane 1) 193 M compound 7 for 30
min at 37°C. Surface proteins were biotin labeled prior to lysis in Brij-97 solution. Clarified lysates were then immunoprecipitated with anti-CD81 (5A6)
and blotted with streptavidin–HRP (C). PBMC were stimulated with suboptimal anti-CD3 (OKT3) and the listed compounds. Prior to incubation with PBMC
each well was washed with RPMI. Proliferation was measured by [3H]thymidine incorporation and scintillation counting (D).
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ration may yield compounds with increased potency and
water solubility, though these goals remain significant chal-
lenges. Given that the current study screened a relatively
small number of compounds (about 100) and given the
power of techniques such as combinatorial chemistry to
explore tens of thousands of related structures, it seems
likely that molecules with better affinity for HCV-E2 can be
developed. The challenge of solubility arises in part because
of the hydrophobic nature of the solvent exposed face of
CD81 helix D that is being mimicked. The use of side
chains with hydrophobic character is almost certainly re-
quired to effectively mimic the binding region on CD81.
Our strategy for future improvements in solubility relies on
the opportunity to modify the linker and to employ polar
character in positions not required for the interaction with
HCV-E2. A comprehensive structure–function analysis is
underway to determine which regions of our current leads
may be forgiving of such changes. These compounds may
represent a novel approach to the possible treatment of HCV
infection or tools for understanding the molecular basis of
HCV-E2 binding to CD81.
Materials and Methods
Cell lines and reagents
Molt-4 and Jurkat human T-cell lines (ATCC; Manassas,
VA) were cultured in RPMI 1640 with 10% fetal bovine
serum at 37°C and 5% CO2. Antibodies used were anti-E2
clone 6F6 (Austral Biologicals; San Ramon, CA), anti-E2
clone H53 (gift from Dr. Jean Dubuisson, Ph.D., Institute de
Biologie de Lille/Institut Pasteur de Lille), and anti-CD81
(5A6). Anti-CD9 (M-L13), anti-CD53 (HI29), anti-CD63
(H5C6), anti-CD81 (JS.81), anti-CD82 (50F11), and anti-
CD151 (14A2.H1) were all from Pharmingen (Franklin
Lakes, NJ). I45DC compounds were dissolved in 100%
DMSO at 100 mM and stored at 20°C. Recombinant
HCV-E2 (Subtype 1a) made in CHO cells covering Ala384
to Lys715 was purchased from Austral Biologicals (San
Ramon, CA).
Synthesis of I45DC compounds
The I45DCs were prepared from imidazole-4,5-dicar-
boxylic acid by the action of thionyl chloride to create an
intermediate pyrazine that was reacted with amines. Oligo-
meric I45DC structures were prepared by first reacting the
pyrazines with amino acid esters followed by reacting the
resulting product with a variety of diamines. The I45DC
products were characterized by 1H and 13C NMR spectros-
copy as well as mass spectrometry (data not shown).
HCV binding assay
I45DC stock solutions at 100 mM in 100% DMSO were
diluted in sterile water and mixed with 0.25 g recombinant
HCV-E2 to yield a solution with 4.8 mM I45DC in 6.25 l
(as indicated in the text, some experiments used varying
concentrations of I45DC compounds) that was incubated at
37°C for 30 min before adding 5  105 Molt-4 cells in 50
l phosphate-buffered saline (PBS) and incubating again at
37°C for 30 min. All reported I45DC concentrations in the
text represent the concentration of the compound as incu-
bated with the Molt-4 cells (not the preincubation concen-
tration). The cells were then washed in PBS and stained for
E2 binding. Briefly, cells were pelleted at 500g after wash-
ing in PBS and resuspended in 100 l PBS containing 1%
BSA and 1 g anti-E2 (6F6 or H53) before placing the
solution on ice for 30 min. The cells were pelleted, washed,
and resuspended in 100 L PBS containing 1% BSA and 2
g goat antimouse Alexa 488 (Molecular Probes; Eugene,
OR). The cells were pelleted and washed before resuspend-
ing in 2% paraformaldehyde and analyzed using a FACS-
caliber flow cytometer (Becton–Dickinson; Franklin Lakes,
NJ) with excitation at 488 nm. Median fluorescence inten-
sity values for 10,000 cells were determined using WinMDI
software (Joseph Trotter, http://facs.scripps.edu).
Coimmunoprecipitation and Western blotting
A total of 2 107 Jurkat T cells were incubated with 193
M compound 7 for 30 min at 37°C. Cells were washed in
PBS, pelleted, and resuspended in PBS with 1 mg/ml
NHS-LC Biotin (Pierce Biotechnology, Inc.; Rockford, IL)
before incubating for 1 h on ice. Cells were then washed
four times in 15 mL PBS prior to lysis on ice for 1 h in TBS
containing EDTA (150 mM NaCl, 5 mM EDTA, 20 mM
Tris, pH 7.5) and 1% Brij-97 (Sigma; St. Louis, MO)
supplemented with 10 U/mL aprotinin (Cal-Biochem; San
Diego, CA), 1 mM PMSF, and 1 g/ml Pepstatin A. Lysates
were clarified by centrifugation 15 min at 21,000g prior to
use. Anti-CD81 antibody (5A6) was captured on protein-A
agarose (Pierce Biotechnology, Inc.; Rockford, IL) at 5 g
mAb/15 L slurry. Antibody was preincubated with the
beads prior to addition of clarified lysate. Samples were
rotated overnight at 4°C. Immunoprecipitated material was
washed four times in lysis buffer, separated on sodium
dodecyl sulfate–polyacrylamide gel electrophoresis and
transferred to PVDF. Biotinylated material was blotted with
streptavidin–HRP (1:2500) (Southern Biotechnology, Bir-
mingham, AL) and visualized using SuperSignal West Pico
Chemiluminescent Substrate (Pierce Biotechnology, Inc.;
Rockville, IL).
Proliferation assay
Ninety-six-well EIA/RIA high protein binding plates
(Corning, Corning, NY) were prebound with 0.1 g/ml
378 S.E. VanCompernolle et al. / Virology 314 (2003) 371–380
anti-CD3 (clone OKT3) alone or with 10 g/ml JS.81 or
H53 in carbonate buffer at 4°C overnight. Wells were then
washed and blocked for 1 h at 37°C in RPMI with 10%
FBS. E2 alone (50 g/ml) or preincubated with 1.5 mM
compound 5 at 37°C for 1 h was subsequently diluted with
PBS (2 g/ml E2, 60 M compound 5) and captured onto
H53 treated wells for 1 h. The wells were then washed in
RPMI for 5 min and incubated with 105 PBMC harvested
from healthy donors and purified by centrifugation through
Lymphoprep (Nycomed Oslo, Norway). After 48 h cells
were pulsed with 1 Ci [3H]thymidine (Perkin–Elmer, Bos-
ton MA) and incubated an additional 12 h. Cellular DNA
was harvested onto glass fiber filtermats and CPM read on
a Perkin–Elmer 1450 Microbeta liquid scintillation and lu-
minescence counter.
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